2017年1月24日星期二

Understanding more about the dinoflagellate's mystical genome

Dinoflagellates usually have a good life when in good times. They live free-floating in the ocean or symbiotically with corals, or as lunch to a host of mollusks, tiny fish and coral species. Some of them make glowing waves at night since they are bioluminescent. However, things will get worse when conditions are wrong. Dinoflagellates poison shellfish beds with red tides and abandon coral reefs to a slow, bleached death.

This happens more and more frequent. In order to find out the answer, UConn marine ecologist Senjie Lin led his research team and sequence the complete genome of dinoflagellate species S. kawagutii, becoming the first one who had done so. The results can be found in journal Science which also publishes other studies on recombinant human proteins.

The species of S. kawagutii is an important endosymbiont of coral reefs, providing them with sugars and nutritious compounds. When it is not present, the corals bleach white, cannot grow and tend to die. However, although metabolic wastes from the coral host provide an enriched supply of nutrients in the otherwise nutrient-poor oceanic habitat, the relation seems to be not enssential S. kawagutii. The researchers guess that when the dinoflagellates don't like the conditions, they can jump ship and turn themselves into impervious little cysts and wait for the right time to ecolonize corals. This performance also can explain that S. kawagutii has an awfully large genome for a symbiont. Usually endosymbionts and parasites depend on the cellular machinery of their hosts and lack many genes that free-living organisms have. So here comes the question: Why does S. kawagutii have so many? No one can explain now.

After analyzing the entire genome of S. kawagutii and comparing it with the genetic codes of related organisms which can be better understood, the team found some surprising things. For instance, they found genes associated with sexual reproduction. S. kawagutii typically reproduces asexually as other dinoflagellates do. A single dinoflagellate will simply split in two. However, when the dinoflagellates turn into cysts, they would reproduce sexually first, which mixes their genetic material with others, maybe in the hope that some of the offspring will gain traits better suited to the stressful environment. But sex related genes have never been found in other dinoflagellates. The results of the study show that K. kawagutii actually has had the bad times in corals.

They also found that S. kawagutii has a gene regulatory system that looks like it could regulate certain genes in corals. That's to say, the dinoflagellates may be manipulating their host's genetic expression in order to make the conditions more comfier for them.

Understanding the S. kawagutii's genome can help researchers better study other dinoflagellates which act many different roles in the ocean ecosystem, thus explaining how the environment changes affecting their way of life. Flarebio offers high-quality recombinant proteins such as recombinant APP at competitive prices.

New technology can track antitumor immune cells

The immunotherapy of using human immune cells to attack cancer cells is the current international scientific research focus, but how specific immune cells in-vivo action has always been a mystery. US researchers have recently developed a new method using recombinant mouse proteins for the first time to achieve the body's immune cell location and surveillance.

At this stage, immunotherapy still has its limitations. The effect of immune cells to find and kill cancer cells sometimes is better than conventional cancer therapy, but sometimes it does not work. Doctors often have to wait a few months to check whether the tumor shrinks to know whether the immune cells attack cancer cells. If immunotherapy does not work, then the cancer cells may have spread or become more difficult to deal with.

Researchers at Stanford University and other researchers said in the online version of the US academic journal Science Translational Medicine that they spent 10 years to find a way to track immune cells.

They have genetically engineered immune cells from patients and added a "reporter gene", a gene that directs the synthesis of a protein that can be detected by positron emission tomography. After injecting genetically-modified immune cells back to the human body, we can know the location of immune cells, the number of information by detecting the relevant proteins to analyse whether they are close to the tumor and attack.

The researchers successfully tested this technique in glioblastoma patients. New technologies can also be used to track immune cells against other cancers.

"The technique, which can show how the living body's immune system works without removing any human tissue, is unprecedented," says professor Sanjff Gambier at Stanford University who led the study.

He introduced, "Immune cell imaging technology also brings a windfall. In one patient's test, some immune cells arrived in the tumor region of the patient's brain, but some of the immune cells went to another region of the brain, where a positron emission tomography revealed a second tumor that had not previously been found."

The researchers said that this can locate the immune cells to see whether it attacks cancer cells and help doctors to assess the effectiveness of immunotherapy for cancer patients and analyze its causes. Flarebio offers high-quality recombinant proteins including recombinant ECE1.

2017年1月23日星期一

Only particular animal species are infected by Salmonella

According to studies on recombinant human proteins, you may know that many strains of Salmonella bacteria are specific to certain species of animals. Some of them may infect cows, pigs, chickens or sheep, still others infect primarily humans.

Recently, a study by a team of scientists from University of Pennsylvania showing that slight variations in the coding sequence of proteins that bind Salmonella to host cells can determine what type of animal a particular strain infects. The findings were gotten using genomic techniques.

The team first focused on the analyses of Salmonella enterica serovar Typhimurium, a leading cause of food poisoning. But it is still a mystery for which the molecular basis for host preferences is.

Single nucleotide polymorphisms (SNPs), variations in the nucleotide sequence of DNA, were identified through the genomic analyses. They found a relatively large number of SNPs, in genes coding for Salmonella surface proteins or secreted factors.

Different host species would share patterns of these so-called non-synonymous SNPs, creating different protein sequences and structures.

Through analyzing of 15 genes in 580 strains of Typhimurium, the team found a high degree of variation and evidence of positive selection and strong evidence that the variation was associated with the particular strains' host specificity.

Further research will be conducted to determine the genetic differences that may separate a strain of Salmonella that causes a brief gastrointestinal illness from one that cause a major systemic disease.

The study was published in the Nature Communications. By the way, Flarebio offers superior recombinant proteins including recombinant Aoc3.

Squalamine can improve the treatment of Parkinson's disease

Scientists report that a compound which occurrs naturally blocks the molecular processes of Parkinson's disease and inhibits its toxic products. The study was completed using recombinant rat proteins by the University of Cambridge and the United States National Institutes of Health and other academic centers in Europe and America.

In the new study, the researchers conducted a series of experiments on the interaction between squalamine, α-synuclein and lipid vesicles. They found that squalamine inhibits protein aggregation by competing for binding sites on the surface of vesicles. By displacing the protein in this manner, it significantly reduces the rate of toxic particle formation. Further tests conducted in human nerve cells show that squalamine inhibits the toxicity of these particles.

Finally, the team tested the effect of squalamine in animal models of Parkinson's disease and used nematodes to express the α-synuclein gene in muscle cells. When the nematode develops, the α-synuclein gene prevents them from moving and the ingestion of salicylamine from the mouth can prevent such paralysis. All the results show that squalamine can be used as a basis for at least some of the symptoms of Parkinson's disease. Researchers said they are planning to conduct clinical trials on Parkinson's patients in the United States.

However, there are further studies to be confirmed, such as the exact benefits of squalamine and drugs may lead to any results. In particular, it is unclear whether squalamine can reach the brain-specific regions of the major molecular processes responsible for Parkinson's disease.

The researchers believe that the initiation of the investigation of salmianol to relieve other symptoms of the effect will be very interesting. By targeting the gastrointestinal system and influencing α-synuclein in the gut, the compound may alleviate severe constipation experienced by the patient. So this treatment can lead to other parts of the body cascade signal, at least in the peripheral nervous system relieve Parkinson's disease. Parkinson's disease has many symptoms. The researchers hope that this compound or its derivatives have a similar mechanism of action to alleviate some of these symptoms and to improve the patient's life at least. Flarebio offers high-quality recombinant proteins like recombinant TLR2 at good prices.

2017年1月22日星期日

The gene Gpr182 has been caught to treat gastrointestinal cancer

Recently, an article published in the journal Clinical Medicine states that scientists have finally seized the Gpr182. Over the years, Gpr182 is like a fugitive criminal, so scientists are helpless. Studies using recombinant dog proteins have shown that Gpr182 can open the door for the treatment of gastrointestinal cancers if a solution can be found.

"The good news is that this is a completely new field. It's especially tempting from a medical point of view, because they shed light on the new g-protein-coupled receptor, a class of cell membrane proteins that are well suited to drugs," the researchers say. 40% of the approved drug target at g protein-coupled receptor. Therefore, the discovery of this new receptor plays a huge role for the understanding of gastrointestinal biology and improves the treatment of colon cancer and other diseases. At present, gastrointestinal cancer is the second leading killer cancer in the United States.

After a series of trials, the researchers found that colorectal cancer patients with colorectal cancer had significantly lower Gpr182 expression compared with healthy colon tissue. Further analysis also suggested that Gpr182 expression reduced in breast cancer, lung cancer and other types of cancer.

At the same time, the results suggest that manipulation of Gpr182 expression or activation may provide a new approach for the treatment of cancer, particularly for the treatment of gastrointestinal cancers. Omera Pharmaceuticals claims to have developed a small molecule that intersects Gpr182 and can help speed drug development. Flarebio offers high-quality recombinant proteins like recombinant ITGB5 at competitive prices.

This gene can control the production of stem cells

When talking about stem cells, it seems hard to judge them. If too many new stem cells are produced, it may lead to cancer, while too few would inhibit the repair and maintenance of the body.

Good news comes here. USC researchers from the lab of Francesca Mariani and colleagues at the University of California, San Diego, (UCSD) published a paper in the Stem Cell Reports. They describe a key gene in maintaining this critical balance between the results of producing too many and too few stem cells. The gene is called Prkci. It influences whether stem cells self-renew to produce more stem cells, or differentiate into more specialized cell types, such as blood or nerves.

The team conducted experiments by growing mouse embryonic stem cells through recombinant rat proteins, which lacked Prkci, into embryo-like structures in the lab. Without Prkci, the stem cells preferred self-renewal, and generated large numbers of stem cells, thus producing an abundance of secondary structures.

After careful inspection, the researchers found that stem cells lacking Prkci had many activated genes typical of stem cells, and some activated genes typical of cardiac, neural, and blood-forming cells. As a consequence, the loss of Prkci can also motivate stem cells to differentiate into the progenitor cells that form neurons, blood and heart muscle.

Prkci activates or deactivates a well-known group of interacting genes that are part of the "Notch signaling pathway to achieve the effects mentioned above. When Prkri is absent, the Notch pathway would produce a protein that signals to stem cells to make more stem cells. When Prkri is present, the Notch pathway just keeps silent and the stem cells all differentiate into specific cell types.

Their findings are good cues for the development of patient therapies. For example, patients with certain injuries or diseases may be benefit from them by using small molecule inhibitors to block the activity of Prkci, thus improve stem cell production. It will be wonderful to apply the findings to the case where stem cells are hard to generate. By the way, Flarebio provides you with superior recombinant proteins like recombinant ITGB5.

2017年1月20日星期五

To better learn transcription factors through SMiLE-seq

EPFL scientists have developed a technique through recombinant rat proteins to make DNA-binding proteins faster, more accurate and more efficient. The results were published in the Jan. 16 issue of Nature-Methods.

The gene contains the DNA code used to produce all the proteins in the cell. To begin the process, the gene must first be transcribed from DNA into RNA. This requires a huge family of DNA-binding proteins called transcription factors, which are of great interest to biologists because of their importance in gene expression. However, due to their pure numbers, their ability to combine into pairs and the difficulty of studying their DNA binding properties in the lab, scientists have known little about transcription factors despite of much effort.

The Bart Deplancke lab at the EPLL Institute of Biotechnology has now invented a new technology called SMiLE-seq, which can greatly accelerate the process with a small amount of transcription factors. The technology uses microfluidics: the science of controlling minute liquids in the same tiny space. Microfluidics is fast becoming an outstanding area of ??EPFL, bringing together many different fields and disciplines.

SMiLE-seq works by adding a small amount of transcription factors (or factors when detecting heterodimers) in microfluidic devices that have microchannel-sized chips that allow liquid to flow therethrough. Once the transcription factor is attached to the surface of the chip, large libraries of random DNA are gently pumped into the chip and flow through them. This allows the transcription factor to recognize its corresponding DNA sequence. Thereafter, the transcription factor-DNA complex is physically captured by dropping the microfluidic control button, and the unbound DNA is simply washed off.

Next, the bound DNA is removed from the device and ready for sequencing to identify which portion is captured by the transcription factor. This information is input into specialized software that allows the researcher to determine the DNA binding properties of transcription factors or heterodimers. This, in turn, helps to better predict the in vivo DNA binding profile.

The use of microfluidics in SMiLE-seq offers three major advantages: First, it reduces the amount of transcription factor required for this type of experiment because it only requires their picogram. Second, it greatly accelerated the experimental process, from a few days to less than an hour. Finally, SMiLE-seq is not limited by the length of the DNA target sequence, nor is it biased towards a stronger affinity protein-DNA interaction. Flarebio provides you with high-quality recombinant proteins like recombinant NPP1 at competitive prices.